Patient Guide: HARNESS-1 (RAC-020) is a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib in patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at multiple participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTACTRN12626000325303
Status: 🟢 Enrolling Now
Condition: epidermal growth factor receptor-mutant non-small cell lung cancer, EGFR-mutant NSCLC
Phase: Phase I

Loading interactive enrollment tools...

The full interactive experience will load momentarily

HARNESS-1 (RAC-020) is a Phase 1a/b clinical trial evaluating RC220 in combination with osimertinib in patients with epidermal growth factor receptor-mutant (EGFR-mutant) non-small cell lung cancer (NSCLC) - Join Clinical Trial NCTACTRN12626000325303

How to Join This Clinical Trial - NCTACTRN12626000325303

Learn how to participate in this Phase I trial studying RC220 for epidermal growth factor receptor-mutant non-small cell lung cancer, EGFR-mutant NSCLC. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with epidermal growth factor receptor-mutant non-small cell lung cancer, EGFR-mutant NSCLC. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
epidermal growth factor receptor-mutant non-small cell lung cancer, EGFR-mutant NSCLC
Treatment Being Tested
RC220
Study Phase
Phase I - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTACTRN12626000325303 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at multiple locations. Find a study site near you:

How to Enroll in This Study

To learn more about participating in this Phase I clinical trial for epidermal growth factor receptor-mutant non-small cell lung cancer, EGFR-mutant NSCLC:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

  • Find clinical trials that match your condition
  • Get matched to the right study location near you
  • Connect directly with study coordinators
  • Understand if you qualify with simplified eligibility screening
  • Navigate the enrollment process with personalized support
  • Access new treatments through clinical research participation